本文へ移動
cccskills
無料GitHub で公開

es-cushing-testing-for-recurrence-lifelong-except-low-ct-density

This skill recommends lifelong biochemical testing for recurrence in all patients with Cushing's syndrome after adrenalectomy, except those with resected adrenal adenoma showing CT density <10 Hounsfield units. Use when determining long‑term follow‑up strategy for a post‑adrenalectomy CS patient; triggers include “post‑adrenalectomy Cushing’s syndrome”, “CT density <10 HU”, and “adrenal adenoma resection”.

インストール方法を見る

含まれるファイル(1)

  • SKILL.md3.4 KB

SKILL.md(原文)

インストールする前に、エージェントに与えられる指示の中身を確認できます。

Testing for Recurrence Throughout Life Except in Patients Who Underwent Resection of Adrenal Adenoma with CT Density <10 Hounsfield Units

STEP 1 — Gather Information

Collect operative report, pathology confirming adrenal adenoma, non‑contrast CT Hounsfield units of the resected lesion, postoperative biochemical remission status (morning cortisol <5 µg/dL and normal late‑night salivary cortisol or urine free cortisol), and baseline comorbidity assessment. Then proceed to assess the CT density threshold.

STEP 2 — Rule In / Rule Out

If the resected adrenal adenoma has a CT density <10 HU and pathology confirms a benign adenoma, rule out the need for lifelong biochemical recurrence testing; otherwise rule in the need for lifelong testing. End decision: skip lifelong testing for low‑density adenoma or move to classification for all others.

STEP 3 — Classify or Stratify

For patients ruled in for lifelong testing, confirm postoperative eucortisolism (morning cortisol <5 µg/dL and normal late‑night salivary cortisol). If eucortisolism is confirmed, proceed to schedule surveillance; if not, manage persistent hypercortisolism per guideline. End decision: confirm remission status to direct surveillance or treat persistent disease.

STEP 4 — Decide

For patients with confirmed eucortisolism, schedule late‑night salivary cortisol or urine free cortisol every 6–12 months indefinitely and continue routine comorbidity monitoring; for patients with persistent hypercortisolism, initiate appropriate treatment (medical, surgical, or radiation) according to the guideline. End decision: implement lifelong surveillance plan or active treatment.

Clinical Guardrails / Mimics / Pitfalls

Do not rely on symptoms alone to exclude recurrence; ensure CT measurement is performed on non‑contrast scans and that the value truly reflects the adenoma (avoid confusing hyperplasia or carcinoma). A single normal test does not guarantee permanent cure; lifelong periodic testing is required unless the low‑density adenoma criterion is met. Misclassifying an adrenal carcinoma as an adenoma with low CT density can lead to inadequate follow‑up.

Concrete Clinical Example

A 48‑year‑old woman underwent left adrenalectomy for a 2.5 cm adenoma; postoperative pathology showed benign adenoma, non‑contrast CT density was 8 HU, and morning cortisol and late‑night salivary cortisol were normal. According to this skill, she does not require lifelong biochemical testing for Cushing’s recurrence, only standard monitoring of hypertension, diabetes, and osteoporosis.

Source: Treatment of Cushing’s Syndrome: An Endocrine Society Clinical Practice Guideline, Nieman et al., 2015, https://doi.org/10.1210/jc.2015-1818

TODO: consider adding scripts/calc.py for the es-cushing-testing-for-recurrence-lifelong-except-low-ct-density calculator

レビュー

まだレビューはありません。使ってみた感想をお寄せください。

同じリポジトリのスキル

概要と使いどころ

Guide pump setting adjustments for the MiniMed 780G system based on CareLink data, using Medtronic's 3-step follow-up workflow. Use when a clinician has CareLink data for a 780G patient and wants to know what to change — which setting, by how much, and how to program it. Triggers include: "what do I adjust", "how to fix high TIR", "how to reduce hypos", "adjust ICR/ISF/basal", "SmartGuard settings", "780G pump settings review", or any question about optimising 780G therapy after reviewing a download.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Performs corticotropin stimulation test to diagnose adrenal insufficiency when morning cortisol is indeterminate (3-15 µg/dL). Triggers include morning cortisol 3-15 µg/dL requiring further AI testing.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Administers immediate parenteral injection of 50–100 mg hydrocortisone for suspected adrenal crisis secondary to adrenal insufficiency. Triggers include hypotension, hypoglycemia, or acute illness in a patient with known adrenal insufficiency.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Clinicians educate adrenal insufficiency patients taking nondexamethasone glucocorticoids who initiate enzyme-inducing antiepileptic drugs about early signs of adrenal insufficiency. Trigger when an AI patient on nondexamethasone GC starts an enzyme-inducing AED such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

In central hypothyroidism patients receiving levothyroxine who initiate enzyme‑inducing antiepileptic drugs, the guideline recommends checking free T4 at least 6 weeks after AED start and increasing the levothyroxine dose if free T4 falls below the target range. Triggers include: central hypothyroidism patient on levothyroxine starting antiepileptic drug such as phenytoin, carbamazepine, or oxcarbazepine.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

Applies serum cortisol cutoffs (<3 μg/dL indicates central adrenal insufficiency; >15 μg/dL likely excludes it) when evaluating morning cortisol for suspected adrenal insufficiency. Triggers include morning cortisol measurement in suspected AI and use when interpreting morning cortisol levels for adrenal insufficiency workup.

日本語の概要は準備中です。原文の説明を表示しています。

dromlakhani/MD2SKILL132026年10月5日 更新

dromlakhani のスキルをすべて見る

このスキルの問題を報告する